About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Publications
Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients
Publications
Risk of adverse events of psoriasis treatment with biologic agents and new small molecules—BIOBADADERM Registry
Publications
Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry
Podcasts
Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies
Podcasts
Author Interview: Doctor David Kellner, September 2025
Publications
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
Publications
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): Two phase 3, randomised, placebo-controlled and active-comparator controlled trials
Podcasts
Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases
Publications
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years
Publications
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: Results through Week 24 of the Phase 3b, randomised, double-blind, placebo-controlled APEX study
Publications
Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis
Podcasts
Discussing RA: Efficacy and safety of upadacitinib for immune-mediated inflammatory disease patients
Publications
Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: Results from the Phase 3 GRAVITI study
Publications
Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients
Publications
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study
Podcasts
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
Publications
A real-world comparison of clinical effectiveness of upadacitinib, tumor necrosis factor inhibitors or interleukin-17 inhibitors in patients with axial spondyloarthritis after switching from an initial tumor necrosis factor inhibitor treatment
Publications
Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
Podcasts
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
Publications
Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient‑years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease
Publications
Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis
Publications
Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)
Publications
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: A pooled analysis of patients from the Phase 3 KEEPsAKE 1 and 2 studies
Publications
Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort
Publications
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy
Podcasts
Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting
Publications
Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: A post hoc analysis from placebo-controlled Phase 3 studies with secukinumab
Publications
A randomized Phase II study of efmarodocokin alfa, an interleukin-22 agonist, versus vedolizumab in patients with ulcerative colitis
Publications
Roflumilast foam, 0.3%, for psoriasis of the scalp and body the ARRECTOR Phase 3 randomized clinical trial
Podcasts
Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025
Publications
Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers
Podcasts